DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20213965

Essential thrombocytosis: review of literature with a rare presentation of cerebral thrombosis treated with endovascular therapy

Aravind V. Datla, Sibasankar Dalai

Abstract


Essential thrombocytosis (ET) is a clonal hematopoietic stem cell disorder. Clinically there is an over-production of platelets without a definable cause. ET is a myeloproliferative neoplasm (MPN). It has an incidence of 1 to 2 per 100,000 population and a distinct female predominance. Once considered a disease of the elderly and responsible for significant morbidity due to haemorrhage or thrombosis, it is now clear that ET can occur at any age in adults and often without symptoms or disturbances of hemostasis. ET can cause both thrombosis or haemorrhage and carries a risk of acute leukemic transformation. Being an MPN, in some cases, polycythemia vera (PV) or primary myelo-fibrosis (PMF) can present as ET. Though the average life expectancy only slightly deviates from the standard expected for age-matched individuals, a thorough understanding of its etiopathogenesis, clinical presentation, complication and management can make a world of difference to patients. Thrombosis is one such complication that has a significant impact on the mortality and morbidity of ET. We proposed using endovascular therapy (EVT) as a treatment modality for cerebral venous sinus thrombosis.


Keywords


Essential thrombocytosis, Hydroxyurea, Myeloproliferative neoplasm, Endovascular therapy, Cerebral venous sinus thrombosis

Full Text:

PDF

References


Cervantes F. Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2011;2011:215-21.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau MML, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.

Spivak JL. Polycythemia vera and other myeloproliferative neoplasms. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison's principles of internal medicine. 20th ed. New York: McGraw Hill Education; 2018: 733-9.

Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol. 2016;91(1):50-8.

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94(1):133-43.

Elala YC, Lasho TL, Gangat N, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91(5):503-6.

Lasho TL, Finke CM, Tischer A, Pardanani A, Tefferi A. Mayo CALR mutation type classifica-tion guide using alpha helix propensity. Am J Hematol. 2018;93(5):128-9.

Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97-105.

Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thro, mbopoietin. Blood. 2004;103(11):4198-200.

Liu K, Martini M, Rocca B, Amos CI, Teofili L, Giona F, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009;94(10):1368-74.

Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 COHORT. Blood. 2008;112(1):141-9.

Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med. 2012;366(10):967-9.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-84.

Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014;89(8):121-4.

Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008;112(3):844-7.

Meier B, Burton JH. Myeloproliferative disorders. Hematol Oncol Clin North Am. 2017;31(6):1029-44.

Accurso V, Santoro M, Mancuso S, Napolitano M, Carlisi M, Mattana M, et al. The essential thrombocythemia in 2020: what we know and where we still have to dig deep. Clin Med Insights Blood Disord. 2020;13:2634853520978210.

Tefferi A, Betti S, Barraco D, Mudireddy M, Shah S, Hanson CA, et al. Gender and survival in essential thrombocythemia: a two-center study of 1,494 patients. Am J Hematol. 2017;92(11):1193-7.

Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma. 1996;22(1):135-42.

Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in mo-lecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-13.

Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets. 2006;17(8):528-44.

Michiels JJ, Abels J, Steketee J, vanVliet H, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and throm- bosis in thrombocythemia. Ann Intern Med. 1985;102(4):466-71.

Passamonti F, Rumi E, Randi ML, Morra E, Cazzola M. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. J Thromb Haemost. 2010;8(2):411-3.

Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol. 2009;82(5):350-3.

Niittyvuopio R, Juvonen E, Kaaja R, Oksanen K, Hallman H, Timonen T, et al. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol. 2004;73(6):431-6.

Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, et al. Aspirin-insensitive thromboxane biosynthesis in essen-tial thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15):3595-603.

Kayacioglu I, Gunay R, Saskin H, Idiz M, Sensoz Y, Ates M, et al. The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. Heart Surg Forum. 2008;11(3):152-7.

Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombo-cythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132-6.

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45.

Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka H, et al. Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: the ANA- HYDRET study, a randomized controlled trial. Blood. 2013;121(10):1720-8.

Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130(17):1889-97.

DeSanctis V, Mazzucconi MG, Spadea A, Alfò M, Mancini M, Bizzoni L, et al. Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol. 2003;123(3):517-521.

Passamonti F, Rumi E, Malabarba L, Arcaini L, Orlandi E, Brusamolino E, et al. Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Ann Hematol. 2004;83(8):495-7.

Shvidel L, Sigler E, Haran M, Klepfish A, Duek A, Berrebi A, et al. Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia. Leukemia. 2007;21(9):2071-2.

Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418-24.

Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med. 2014;371(2):188-9.

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857-9.

Falchi L, Kantarjian HM, Verstovsek S. Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. Leukemia. 2017;31(9):1845-4.

Andriani A, Latagliata R, Anaclerico B. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1,297 patients. Am J Hematol. 2016;91(3):318-21.

Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005; 352(17):1791-8.

Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6(2):162-70.

Banakar BF, Hiregoudar V. Clinical profile, outcome, and prognostic factors of cortical venous thrombosis in a tertiary care hospital, India. J Neurosci Rural Pract. 2017;8(2):204-8.

Capecchi M, Abbattista M, Martinelli I. Cerebral venous sinus thrombosis. J Thromb Haemost. 2018;16(10):1918-31.

Liao CH, Liao NC, Chen WH, Chen H, Shen C, Yang S, et al. Endovascular mechanical thrombectomy and on-site chemical thrombolysis for severe cerebral venous sinus thrombosis. Sci Rep. 2020;10(1):4937.

Dmytriw AA, Song JS, Yu E, Poon CS. Cerebral venous thrombosis: state of the art diagnosis and management. Neuroradiol. 2018;6(7)0:669-85.

Yang X, Wu F, Liu Y, Duan J, Meng R, Chen J, et al. Predictors of successful endovascular treatment in severe cerebral venous sinus thrombosis. Ann Clin Transl Neurol. 2019;6(4):755-61.